Exploratory Efficacy Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.

United statesNorth carolinaDuke universityJohn alexanderManesh patelAmerican heart associationChristian ruffScientific sessionsExploratory efficacy endpointsMedscape cardiologyAtrial fibrillationF atrial fibrillationAnticoagulation therapyErebrovascular accidentVa cerebrovascular accidentVenous thromboembolism